State Street Corp Decreases Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

State Street Corp lessened its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 23.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 849,470 shares of the company’s stock after selling 262,022 shares during the period. State Street Corp owned 0.22% of GoodRx worth $5,895,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Rubric Capital Management LP grew its holdings in shares of GoodRx by 25.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after acquiring an additional 943,226 shares during the period. Millennium Management LLC grew its position in GoodRx by 36.5% during the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares during the last quarter. American Century Companies Inc. bought a new stake in GoodRx during the 2nd quarter valued at about $18,183,000. Point72 Asset Management L.P. purchased a new position in GoodRx in the 3rd quarter worth approximately $11,295,000. Finally, Picton Mahoney Asset Management lifted its holdings in shares of GoodRx by 24.3% during the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after purchasing an additional 118,703 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

GDRX has been the topic of several research reports. Barclays dropped their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Mizuho started coverage on shares of GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Finally, Citigroup dropped their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.37.

GoodRx Stock Up 2.2 %

Shares of NASDAQ:GDRX opened at $4.62 on Friday. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -154.00, a PEG ratio of 3.54 and a beta of 1.29. The business has a 50-day moving average price of $5.09 and a 200 day moving average price of $6.82. GoodRx Holdings, Inc. has a 12-month low of $4.09 and a 12-month high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.